Ten big names stood out during the trading session on Wednesday—eight of which propelled to new all-time highs—on the back of company-specific catalysts buoying investing appetite.
The 10 stocks outperformed a lackluster performance on Wall Street, with the three major indices finishing mixed. The Dow Jones was the sole gainer, up 0.57 percent. In contrast, the S&P 500 and the tech-heavy Nasdaq both dropped by 0.10 percent and 0.33 percent, respectively.
In this article, we focus on the performance of the top 10 performers on Wednesday and break down the reasons behind their gains.
To come up with the list, we considered only the stocks with at least $2 billion in market capitalization and 5 million shares in trading volume.
Source: Federal Reserve
10. Hologic Inc. (NASDAQ:HOLX)
Shares of Hologic Inc. rallied by 7.69 percent on Wednesday to close at $68.20 as investors repositioned portfolios amid reports that it was again in talks with two investment companies for a potential sale.
According to a report by Bloomberg, Hologic Inc. (NASDAQ:HOLX) has received a new acquisition offer from Blackstone Inc. and TPG Inc. after earlier negotiations resulted in a failed takeover.
Bloomberg said the two firms are now undergoing due diligence, but noted that negotiations could still falter.
Earlier this year, Blackstone and TPG have offered to acquire Hologic Inc. (NASDAQ:HOLX) for $16.7 billion, a proposal which was rejected and would have been one of the largest leveraged buyouts this year.
In its updated report, Hologic Inc. (NASDAQ:HOLX) raised its revenue forecast for the full fiscal year of 2025 to between $4.08 billion to $4.09 billion, from $4.05 billion to $4.1 billion earlier.
For the fourth quarter alone, revenues are expected to hit $1.03 billion to $1.04 billion.
9. Roivant Sciences Ltd. (NASDAQ:ROIV)
Roivant Sciences jumped to a new all-time high on Wednesday, as investors cheered impressive results from the third phase of its clinical trial for its drug treatment for an autoimmune disease.
At intra-day session, Roivant Sciences Ltd. (NASDAQ:ROIV) soared to as high as $16.05 before trimming gains to end the day just up by 7.76 percent at $15.28.
This followed positive results from the phase 3 clinical trial of drug candidate Brepocitinib for the treatment of dermatomyositis (DM), where it saw significant and constant developments in as early as week 4.
The clinical trial was in partnership with Priovant Therapeutics.
Roivant Sciences Ltd. (NASDAQ:ROIV) said Brepocitinib 30 mg achieved a total improvement score (TIS) of 46.5 as compared with the 31.2 for the placebo.
Additionally, the drug candidate demonstrated clinically meaningful improvement over placebo across all nine key secondary endpoints.
It said adverse events of special interest (AESIs), which included malignancy, cardiovascular events, and thromboembolic events, did not occur with higher frequency of taking the brepocitinib 30 mg.
Dermatomyositis (DM) is a multi-organ idiopathic inflammatory condition that affects approximately 50,000 adults in the United States. It is characterized by debilitating muscle weakness and skin lesions.
Hedge Fund Resource Center